- ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
- Several approaches have been taken to enhance immunity against tumors in humans. These strategies target either the adaptive immune responses, i.e T cells and B cells, or enhance the activity of antigen presenting cells (APC) such as dendritic cells (DC). Dr. Sabado is involved in developing new approaches to enhance the activity of DCs in vivo. Although early clinical trials have established the ability of DC immunotherapy to exploit a patient’s own immune system to induce anti-tumor immune responses, clinical success have been limited. Therefore, she is involved in clinical trials testing various adjuvants to generate potent immunostimulatory DCs as well as in combination with other agents to generate potent immune responses in vivo.
Dr. Sabado is the facility director of the Vaccine and Cell Therapy Laboratory (VCTL). The VCTL is a dedicated and controlled facility for the manufacturing of immunotherapies and testing their effectiveness in vaccinated patients for phase I and II clinical trials and infectious diseases.
Sabado RL, Bhardwaj N. Dendritic cell immunotherapy. Annals of the New York Academy of Sciences 2013 May; 1284.
Sabado RL, Miller E, Spadaccia M, Vengco I, Hasan F, Bhardwaj N. Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. Journal of visualized experiments : JoVE 2013;(78).
Miller E, Spadaccia M, Sabado R, Chertova E, Bess J, Trubey CM, Holman RM, Salazar A, Lifson J, Bhardwaj N. Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. Vaccine 2015 Jan; 33(2).
Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg JD, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer immunology research 2015 Mar; 3(3).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Sabado did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.
Hess CSM Building Floor 5 Room 5-110
1470 Madison Avenue
New York, NY 10029